Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer of the prostate.
Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Bracarda S, et al. Crit Rev Oncol Hematol. 2005 Dec;56(3):379-96. doi: 10.1016/j.critrevonc.2005.03.010. Crit Rev Oncol Hematol. 2005. PMID: 16310371 Review.
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda S, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B. Bracarda S, et al. BJU Int. 2011 Jan;107(2):214-9. doi: 10.1111/j.1464-410X.2010.09707.x. Epub 2010 Oct 13. BJU Int. 2011. PMID: 20942831 Clinical Trial.
Biologic tools to personalize treatment in genitourinary cancers.
Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Bracarda S, et al. Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e42-8. doi: 10.1016/j.critrevonc.2010.09.008. Epub 2011 Jan 12. Crit Rev Oncol Hematol. 2012. PMID: 21232974 Review.
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Bracarda S, Porta C, Boni C, Santoro A, Mucciarini C, Pazzola A, Cortesi E, Gasparro D, Labianca R, Di Costanzo F, Falcone A, Cinquini M, Caserta C, Paglino C, De Angelis V. Bracarda S, et al. Eur Urol. 2013 Feb;63(2):254-61. doi: 10.1016/j.eururo.2012.08.027. Epub 2012 Aug 23. Eur Urol. 2013. PMID: 22964169 Clinical Trial.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Bracarda S, et al. Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3. Future Oncol. 2014. PMID: 24295376 Free article. Clinical Trial.
226 results